Cardiogenic Shock: A Summary of the Randomized SHOCK Trial

Venu Menon, MD, Rupert Fincke, MD


CHF. 2003;9(1) 

In This Article


Although there was no benefit at 30 days, among patients in CS due to LV dysfunction associated with an ST elevation MI, a strategy of ERV was superior to IMS at 6 and 12 months of follow-up. Patients younger than 75 years of age benefited most, with 20 lives saved at 6 months per 100 patients treated. According to the results of the SHOCK trial, ERV is now a class I indication for this patient population in the ACC/AHA myocardical infarction guidelines.[22] Mortality with CABG was similar to that with percutaneous intervention in this high-risk population.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.